93 results
Page 3 of 5
424B3
xqsv6sy 5seleap
14 Jul 20
Prospectus supplement
4:05pm
8-K
EX-99.1
obotr34p5eyxn1
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-99.1
8lhzso2is6rmh6pjqrwt
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
21wb7p7o
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
br6krzi3k5qd 1s0
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
6hpln25n5fb6dmr
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
ht53v4emp46gqwc rdgm
13 Jan 20
Other Events
8:06am
8-K
EX-99.1
7q8ks4z0c
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
o6twvzsw
20 Dec 19
Regulation FD Disclosure
8:10am
8-K
EX-99.1
sj0rujvtog
2 Dec 19
Other Events
5:18pm
8-K
EX-99.2
icp3yb1vtmcu
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
8-K
EX-99.1
rumyl7ubrvy
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
424B5
6vg513 64guhl13m3w
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
aolkqql 2i54nti39h
26 Nov 19
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.2
5j5z41
20 Nov 19
Other Events
7:05am
8-K
EX-99.1
0osgtal3uodn4iv1b
20 Nov 19
Other Events
7:05am